Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H16O5 |
| Molecular Weight | 288.2952 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)=CC[C@@H](O)C1=CC(=O)C2=C(O)C=CC(O)=C2C1=O
InChI
InChIKey=NEZONWMXZKDMKF-SNVBAGLBSA-N
InChI=1S/C16H16O5/c1-8(2)3-4-10(17)9-7-13(20)14-11(18)5-6-12(19)15(14)16(9)21/h3,5-7,10,17-19H,4H2,1-2H3/t10-/m1/s1
Shikonin is a major naphthoquinone compound found in the roots of Lithospermum erythrorhizon and exhibits powerful anticancer activities for various cancer cells. Shikonin and its derivatives are characterized by a wide spectrum of antibacterial activities: high antibacterial activity towards Gram-positive bacteria (Staphylococcus aureus et al.), a stable fungicidal effect towards Candida and Trichosporon fungi. Shikonin normalizes the production of the key mediators of inflammation IL-1 and IL-2, IFN-γ, reduces vascular permeability in the focus of inflammation, exhibiting a marked anti-inflammatory effect. Combined therapy with applications of a bio-polymeric film with shikonin and its esters (naphthoquinone derivatives) led to an obvious improvement of the clinical parameters and reduced the morphological signs of the buccal mucosal lesions. The drug was well tolerated by all patients and no side effects were recorded. Shikonin, as a naturally occurring, low-molecular-weight pan-chemokine receptor inhibitor, constitutes a basis for the development of novel anti-HIV therapeutic agents.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1075189 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29185365 |
8.82 µM [IC50] | ||
Target ID: map04210 |
|||
Target ID: CHEMBL2413 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11360924 |
2.57 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Functional and mechanistic investigation of Shikonin in scarring. | 2015-02-25 |
|
| Shikonin, a constituent of Lithospermum erythrorhizon exhibits anti-allergic effects by suppressing orphan nuclear receptor Nr4a family gene expression as a new prototype of calcineurin inhibitors in mast cells. | 2014-12-05 |
|
| Shikonin time-dependently induced necrosis or apoptosis in gastric cancer cells via generation of reactive oxygen species. | 2014-03-25 |
|
| Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway. | 2013-06-07 |
|
| Shikonin induces programmed necrosis-like cell death through the formation of receptor interacting protein 1 and 3 complex. | 2013-05 |
|
| [Effect of shikonin, a phytocompound from Lithospermum erythrorhizon, on rat vascular smooth muscle cells proliferation and apoptosis in vitro]. | 2005-06-08 |
|
| Screening of the inhibitory effect of vegetable constituents on the aryl hydrocarbon receptor-mediated activity induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. | 2003-12 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24319756
Biopolymeric films local application to foci of lesions 3 times daily over 3 weeks.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12936978
Shikonin inhibited the replication of a multidrug-resistant HIV1 strain and pediatric clinical isolates of HIV in human peripheral blood mononuclear cells, with 50% inhibitory concentrations (IC(50)s) ranging from 96 to 366 nM. Shikonin also effectively inhibited the replication of the HIV Ba-L isolate in monocytes/macrophages, with an IC(50) of 470 nM.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
517-89-5
Created by
admin on Mon Mar 31 21:51:33 GMT 2025 , Edited by admin on Mon Mar 31 21:51:33 GMT 2025
|
PRIMARY | |||
|
252844
Created by
admin on Mon Mar 31 21:51:33 GMT 2025 , Edited by admin on Mon Mar 31 21:51:33 GMT 2025
|
PRIMARY | |||
|
DTXSID30199653
Created by
admin on Mon Mar 31 21:51:33 GMT 2025 , Edited by admin on Mon Mar 31 21:51:33 GMT 2025
|
PRIMARY | |||
|
8100
Created by
admin on Mon Mar 31 21:51:33 GMT 2025 , Edited by admin on Mon Mar 31 21:51:33 GMT 2025
|
PRIMARY | |||
|
3IK6592UBW
Created by
admin on Mon Mar 31 21:51:33 GMT 2025 , Edited by admin on Mon Mar 31 21:51:33 GMT 2025
|
PRIMARY | |||
|
479503
Created by
admin on Mon Mar 31 21:51:33 GMT 2025 , Edited by admin on Mon Mar 31 21:51:33 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD